| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.16 | 0.009 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.17 | 0.009 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.009 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.009 |